FDA review of dupilumab for chronic spontaneous urticaria

Published Date: 13 Mar 2023

The FDA approval request for CSU is based on data from a pair of Phase 3 trials in two different populations.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Reducing social media to an hour a day boosts young people's self-image.

2.

CD39 Blockade Shows Potential in Early-Stage Lung Cancer

3.

In high-risk muscle invasive urothelial cancer, adjuvant pembrolizumab improves disease-free survival.

4.

A prostate cancer risk prediction algorithm could help target men at highest risk

5.

FDA Approves Iberdomide Combo for Multiple Myeloma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot